Short Interest in MDB Capital Holdings, LLC (NASDAQ:MDBH) Decreases By 31.5%

MDB Capital Holdings, LLC (NASDAQ:MDBH) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 4,239 shares, a drop of 31.5% from the March 15th total of 6,192 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 3,339 shares, the days-to-cover ratio is currently 1.3 days.

MDB Capital Stock Performance

NASDAQ:MDBH traded up $0.05 during trading hours on Thursday, reaching $3.56. The stock had a trading volume of 1,533 shares, compared to its average volume of 6,878. MDB Capital has a 52 week low of $2.75 and a 52 week high of $5.50. The company has a 50 day moving average price of $3.11 and a two-hundred day moving average price of $3.38. The stock has a market capitalization of $36.67 million, a PE ratio of -1.67 and a beta of 0.93.

MDB Capital (NASDAQ:MDBH) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.18) earnings per share (EPS) for the quarter.

Institutional Trading of MDB Capital

A number of large investors have recently added to or reduced their stakes in the company. DRW Securities LLC bought a new stake in MDB Capital in the 4th quarter worth approximately $40,000. Citadel Advisors LLC bought a new position in shares of MDB Capital during the 3rd quarter valued at approximately $43,000. Finally, Raymond James Financial Inc. bought a new position in shares of MDB Capital during the 2nd quarter valued at approximately $27,000. Institutional investors own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of MDB Capital in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, MDB Capital presently has an average rating of “Sell”.

About MDB Capital

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.